Sign In

Login

Password

Forgot Password ? Sign Up

Rak żołądka człowieka (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rak żołądka człowieka" in Polish language version.

refsWebsite
Global rank Polish rank
201nih.gov
4th place
7th place
121doi.org
2nd place
6th place
10google.pl
low place
557th place
6web.archive.org
1st place
1st place
3termedia.pl
low place
624th place
3ascopubs.org
low place
8,458th place
2springer.com
274th place
376th place
1who.int
195th place
256th place
1onkologia.org.pl
low place
8,813th place
1cancer-therapy.org
low place
low place
1mayoclinic.org
1,610th place
4,301st place
1scirp.org
low place
5,327th place
1discoverymedicine.com
low place
low place
1mp.pl
8,738th place
165th place
1nejm.org
2,374th place
2,071st place
1zalecenia.med.pl
low place
low place
1lsmuni.lt
low place
low place
1aacrjournals.org
8,869th place
9,541st place
1vetpol.org.pl
low place
3,193rd place

aacrjournals.org

cancerres.aacrjournals.org

ascopubs.org

jco.ascopubs.org

ascopubs.org

cancer-therapy.org

discoverymedicine.com

doi.org

  • A. Jemal, F. Bray, M.M. Center, J. Ferlay i inni. Global cancer statistics. „CA Cancer J Clin”. 61 (2). s. 69–90. DOI: 10.3322/caac.20107. PMID: 21296855. 
  • Z. Jin, W. Jiang, L. Wang. Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review). „Oncol Lett”. 9 (4), s. 1502–1508, Apr 2015. DOI: 10.3892/ol.2015.2959. PMID: 25788990. 
  • M. Inoue, S. Tsugane. Epidemiology of gastric cancer in Japan. „Postgrad Med J”. 81 (957), s. 419–424, Jul 2005. DOI: 10.1136/pgmj.2004.029330. PMID: 15998815. 
  • N. Uemura, S. Okamoto, S. Yamamoto, N. Matsumura i inni. Helicobacter pylori infection and the development of gastric cancer. „N Engl J Med”. 345 (11), s. 784–789, Sep 2001. DOI: 10.1056/NEJMoa001999. PMID: 11556297. 
  • J. Parsonnet, G.D. Friedman, D.P. Vandersteen, Y. Chang i inni. Helicobacter pylori infection and the risk of gastric carcinoma. „N Engl J Med”. 325 (16), s. 1127–1131, Oct 1991. DOI: 10.1056/NEJM199110173251603. PMID: 1891020. 
  • A. Nomura, G.N. Stemmermann, P.H. Chyou, I. Kato i inni. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. „N Engl J Med”. 325 (16), s. 1132–1136, Oct 1991. DOI: 10.1056/NEJM199110173251604. PMID: 1891021. 
  • M.J. Blaser. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. „J Infect Dis”. 179 (6), s. 1523–1530, Jun 1999. DOI: 10.1086/314785. PMID: 10228075. 
  • L. D’Elia, G. Rossi, R. Ippolito, F.P. Cappuccio i inni. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. „Clin Nutr”. 31 (4), s. 489–498, Aug 2012. DOI: 10.1016/j.clnu.2012.01.003. PMID: 22296873. 
  • M. Kobayashi, Y. Tsubono, S. Sasazuki, S. Sasaki i inni. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I. „Int J Cancer”. 102 (1), s. 39–44, Nov 2002. DOI: 10.1002/ijc.10659. PMID: 12353232. 
  • Y. Zhou, W. Zhuang, W. Hu, G.J. Liu i inni. Consumption of large amounts of Allium vegetables reduces risk for gastric cancer in a meta-analysis. „Gastroenterology”. 141 (1), s. 80–89, 2011. DOI: 10.1053/j.gastro.2011.03.057. PMID: 21473867. 
  • V. Guercio, C. Galeone, F. Turati, C. La Vecchia. Gastric cancer and allium vegetable intake: a critical review of the experimental and epidemiologic evidence. „Nutr Cancer”. 66 (5), s. 757–773, 2014. DOI: 10.1080/01635581.2014.904911. PMID: 24820444. 
  • F. Turati, C. Pelucchi, V. Guercio, C. La Vecchia i inni. Allium vegetable intake and gastric cancer: a case-control study and meta-analysis. „Mol Nutr Food Res”. 59 (1), s. 171–179, 2015. DOI: 10.1002/mnfr.201400496. PMID: 25215621. 
  • P. Guilford, J. Hopkins, J. Harraway, M. McLeod i inni. E-cadherin germline mutations in familial gastric cancer. „Nature”. 392 (6674), s. 402–405, Mar 1998. DOI: 10.1038/32918. PMID: 9537325. 
  • R.C. Fitzgerald, R. Hardwick, D. Huntsman, F. Carneiro i inni. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. „J Med Genet”. 47 (7), s. 436–444, 2010. DOI: 10.1136/jmg.2009.074237. PMID: 20591882. 
  • S. Masciari, N. Larsson, J. Senz, N. Boyd i inni. Germline E-cadherin mutations in familial lobular breast cancer. „J Med Genet”. 44 (11), s. 726–731, Nov 2007. DOI: 10.1136/jmg.2007.051268. PMID: 17660459. 
  • W. Cichy, B. Klincewicz, A. Plawski. Juvenile polyposis syndrome. „Arch Med Sci”. 10 (3), s. 570–577, Jun 2014. DOI: 10.5114/aoms.2014.43750. PMID: 25097590. 
  • A. Hemminki, D. Markie, I. Tomlinson, E. Avizienyte i inni. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. „Nature”. 391 (6663), s. 184–187, Jan 1998. DOI: 10.1038/34432. PMID: 9428765. 
  • C.A. González, G. Pera, A. Agudo, D. Palli i inni. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). „Int J Cancer”. 107 (4), s. 629–634, Nov 2003. DOI: 10.1002/ijc.11426. PMID: 14520702. 
  • A. Chao, M.J. Thun, S.J. Henley, E.J. Jacobs i inni. Cigarette smoking, use of other tobacco products and stomach cancer mortality in US adults: The Cancer Prevention Study II. „Int J Cancer”. 101 (4), s. 380–389, Oct 2002. DOI: 10.1002/ijc.10614. PMID: 12209964. 
  • Y. Koizumi, Y. Tsubono, N. Nakaya, S. Kuriyama i inni. Cigarette smoking and the risk of gastric cancer: a pooled analysis of two prospective studies in Japan. „Int J Cancer”. 112 (6), s. 1049–1055, Dec 2004. DOI: 10.1002/ijc.20518. PMID: 15386347. 
  • V. Pasechnikov, S. Chukov, E. Fedorov, I. Kikuste i inni. Gastric cancer: prevention, screening and early diagnosis. „World J Gastroenterol”. 20 (38), s. 13842–13862, Oct 2014. DOI: 10.3748/wjg.v20.i38.13842. PMID: 25320521. 
  • T. Waddell, M. Verheij, W. Allum, D. Cunningham i inni. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. „Ann Oncol”. 24 Suppl 6, s. vi57–63, Oct 2013. DOI: 10.1093/annonc/mdt344. PMID: 24078663. 
  • T. de Figueiredo Soares, D.M. de Magalhães Queiroz, E.N. Mendes, G.A. Rocha i inni. The interrelationship between Helicobacter pylori vacuolating cytotoxin and gastric carcinoma. „Am J Gastroenterol”. 93 (10), s. 1841–1847, Oct 1998. DOI: 10.1111/j.1572-0241.1998.533_d.x. PMID: 9772042. 
  • A. Yanai, Y. Hirata, Y. Mitsuno, S. Maeda i inni. Helicobacter pylori induces antiapoptosis through buclear factor-kappaB activation. „J Infect Dis”. 188 (11), s. 1741–1751, Dec 2003. DOI: 10.1086/379629. PMID: 14639546. 
  • B. Hu, N. El Hajj, S. Sittler, N. Lammert i inni. Gastric cancer: Classification, histology and application of molecular pathology. „J Gastrointest Oncol”. 3 (3), s. 251–261, Sep 2012. DOI: 10.3978/j.issn.2078-6891.2012.021. PMID: 22943016. 
  • S. Kaneko, T. Yoshimura. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975–1989. „Br J Cancer”. 84 (3), s. 400–405, Feb 2001. DOI: 10.1054/bjoc.2000.1602. PMID: 11161407. 
  • M. Qiu, Y. Zhou, X. Zhang, Z. Wang i inni. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. „BMC Cancer”. 14, s. 823, 2014. DOI: 10.1186/1471-2407-14-823. PMID: 25380654. 
  • F. Berlth, E. Bollschweiler, U. Drebber, A.H. Hoelscher i inni. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. „World J Gastroenterol”. 20 (19), s. 5679–5684, May 2014. DOI: 10.3748/wjg.v20.i19.5679. PMID: 24914328. 
  • J.R. Siewert, H.J. Stein. Classification of adenocarcinoma of the oesophagogastric junction. „Br J Surg”. 85 (11), s. 1457–1459, Nov 1998. DOI: 10.1046/j.1365-2168.1998.00940.x. PMID: 9823902. 
  • J. Fujisaki, T. Nakajima, T. Hirasawa, Y. Yamamoto i inni. Natural history of gastric cancer-a case followed up for eight years: early to advanced gastric cancer. „Clin J Gastroenterol”. 5 (5), s. 351–354, Oct 2012. DOI: 10.1007/s12328-012-0325-2. PMID: 23087768. 
  • J.T. Hallinan, S.K. Venkatesh. Gastric carcinoma: imaging diagnosis, staging and assessment of treatment response. „Cancer Imaging”. 13, s. 212–227, 2013. DOI: 10.1102/1470-7330.2013.0023. PMID: 23722535. 
  • O. Hosokawa, S. Tsuda, E. Kidani, K. Watanabe i inni. Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. „Endoscopy”. 30 (8), s. 669–674, Oct 1998. DOI: 10.1055/s-2007-1001386. PMID: 9865554. 
  • X.M. Meng, Y. Zhou, T. Dang, X.Y. Tian i inni. Magnifying chromoendoscopy combined with immunohistochemical staining for early diagnosis of gastric cancer. „World J Gastroenterol”. 19 (3), s. 404–410, Jan 2013. DOI: 10.3748/wjg.v19.i3.404. PMID: 23372365. 
  • D. Bentrem, H. Gerdes, L. Tang, M. Brennan i inni. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. „Ann Surg Oncol”. 14 (6), s. 1853–1859, Jun 2007. DOI: 10.1245/s10434-006-9037-5. PMID: 17357856. 
  • M.A. Mekky, K. Yamao, A. Sawaki, N. Mizuno i inni. Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors. „Gastrointest Endosc”. 71 (6), s. 913–919, May 2010. DOI: 10.1016/j.gie.2009.11.044. PMID: 20226456. 
  • C.Y. Chen, J.S. Hsu, D.C. Wu, W.Y. Kang i inni. Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results. „Radiology”. 242 (2), s. 472–482, Feb 2007. DOI: 10.1148/radiol.2422051557. PMID: 17255419. 
  • H.J. Kim, A.Y. Kim, S.T. Oh, J.S. Kim i inni. Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning. „Radiology”. 236 (3), s. 879–885, Sep 2005. DOI: 10.1148/radiol.2363041101. PMID: 16020558. 
  • D.M. Yang, H.C. Kim, W. Jin, C.W. Ryu i inni. 64 multidetector-row computed tomography for preoperative evaluation of gastric cancer: histological correlation. „J Comput Assist Tomogr”. 31 (1). s. 98–103. DOI: 10.1097/01.rct.0000234072.16209.ab. PMID: 17259840. 
  • B.B. Chen, P.C. Liang, K.L. Liu, J.K. Hsiao i inni. Preoperative diagnosis of gastric tumors by three-dimensional multidetector row ct and double contrast barium meal study: correlation with surgical and histologic results. „J Formos Med Assoc”. 106 (11), s. 943–952, Nov 2007. DOI: 10.1016/S0929-6646(08)60065-0. PMID: 18063516. 
  • M. Yun. Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT. „J Gastric Cancer”. 14 (1), s. 1–6, Mar 2014. DOI: 10.5230/jgc.2014.14.1.1. PMID: 24765531. 
  • C.X. Wu, Z.H. Zhu. Diagnosis and evaluation of gastric cancer by positron emission tomography. „World J Gastroenterol”. 20 (16), s. 4574–4585, Apr 2014. DOI: 10.3748/wjg.v20.i16.4574. PMID: 24782610. 
  • A.E. Dassen, D.J. Lips, C.J. Hoekstra, J.F. Pruijt i inni. FDG-PET has no definite role in preoperative imaging in gastric cancer. „Eur J Surg Oncol”. 35 (5), s. 449–455, May 2009. DOI: 10.1016/j.ejso.2008.11.010. PMID: 19147324. 
  • H. Shimada, S. Okazumi, M. Koyama, K. Murakami. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of ¹⁸F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. „Gastric Cancer”. 14 (1), s. 13–21, Mar 2011. DOI: 10.1007/s10120-011-0017-5. PMID: 21331531. 
  • H. Hur, S.H. Kim, W. Kim, K.Y. Song i inni. The efficacy of preoperative PET/CT for prediction of curability in surgery for locally advanced gastric carcinoma. „World J Surg Oncol”. 8, s. 86, 2010. DOI: 10.1186/1477-7819-8-86. PMID: 20932345. 
  • E. Smyth, H. Schöder, V.E. Strong, M. Capanu i inni. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. „Cancer”. 118 (22), s. 5481–5488, Nov 2012. DOI: 10.1002/cncr.27550. PMID: 22549558. 
  • K. Mukai, Y. Ishida, K. Okajima, H. Isozaki i inni. Usefulness of preoperative FDG-PET for detection of gastric cancer. „Gastric Cancer”. 9 (3), s. 192–196, 2006. DOI: 10.1007/s10120-006-0374-7. PMID: 16952037. 
  • M. Tanner, M. Hollmén, T.T. Junttila, A.I. Kapanen i inni. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. „Ann Oncol”. 16 (2), s. 273–278, Feb 2005. DOI: 10.1093/annonc/mdi064. PMID: 15668283. 
  • B. Yan, E.X. Yau, S.S. Bte Omar, C.W. Ong i inni. A study of HER2 gene amplification and protein expression in gastric cancer. „J Clin Pathol”. 63 (9), s. 839–842, Sep 2010. DOI: 10.1136/jcp.2010.076570. PMID: 20696687. 
  • C. Gómez-Martin, E. Garralda, M.J. Echarri, A. Ballesteros i inni. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. „J Clin Pathol”. 65 (8), s. 751–757, Aug 2012. DOI: 10.1136/jclinpath-2012-200774. PMID: 22569536. 
  • J.T. Jørgensen, M. Hersom. HER2 as a Prognostic Marker in Gastric Cancer – A Systematic Analysis of Data from the Literature. „J Cancer”. 3, s. 137–144, 2012. DOI: 10.7150/jca.4090. PMID: 22481979. 
  • T.C. Chua, N.D. Merrett. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. „Int J Cancer”. 130 (12), s. 2845–2856, Jun 2012. DOI: 10.1002/ijc.26292. PMID: 21780108. 
  • E. Ucar, E. Semerci, H. Ustun, T. Yetim i inni. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. „Adv Ther”. 25 (10), s. 1075–1084, Oct 2008. DOI: 10.1007/s12325-008-0100-4. PMID: 18821070. 
  • D. Marrelli, F. Roviello, A. De Stefano, M. Farnetani i inni. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. „Oncology”. 57 (1), s. 55–62, Jul 1999. DOI: 10.1159/000012001. PMID: 10394126. 
  • K. Deng, L. Yang, B. Hu, H. Wu i inni. The Prognostic Significance of Pretreatment Serum CEA Levels in Gastric Cancer: A Meta-Analysis Including 14651 Patients. „PLoS One”. 10 (4), s. e0124151, 2015. DOI: 10.1371/journal.pone.0124151. PMID: 25879931. 
  • E. Polat, U. Duman, M. Duman, K. Derya Peker i inni. Preoperative serum tumor marker levels in gastric cancer. „Pak J Med Sci”. 30 (1), s. 145–149, Jan 2014. DOI: 10.12669/pjms.301.3968. PMID: 24639849. 
  • M.J. Gaspar, I. Arribas, M.C. Coca, M. Díez-Alonso. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. „Tumour Biol”. 22 (5). s. 318–322. DOI: 10.1159/000050633. PMID: 11553862. 
  • J. Chen, J.H. Cheong, M.J. Yun, J. Kim i inni. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. „Cancer”. 103 (11), s. 2383–2390, Jun 2005. DOI: 10.1002/cncr.21074. PMID: 15856477. 
  • K. Borch, B. Jönsson, E. Tarpila, T. Franzén i inni. Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. „Br J Surg”. 87 (5), s. 618–626, May 2000. DOI: 10.1046/j.1365-2168.2000.01425.x. PMID: 10792320. 
  • J. Pinto-De-Sousa, L. David, M. Seixas, A. Pimenta. Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. „Dig Surg”. 18 (2), s. 102–110, 2001. DOI: 10.1159/000050109. PMID: 11351154. 
  • H.G. Hass, U. Smith, C. Jäger, M. Schäffer i inni. Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren’s): single-center experience of 160 cases. „Onkologie”. 34 (12), s. 682–686, 2011. DOI: 10.1159/000334545. PMID: 22156447. 
  • D.A. Kooby, A. Suriawinata, D.S. Klimstra, M.F. Brennan i inni. Biologic predictors of survival in node-negative gastric cancer. „Ann Surg”. 237 (6), s. 828–835; discussion 835–783, Jun 2003. DOI: 10.1097/01.SLA.0000072260.77776.39. PMID: 12796579. 
  • K. Washington. 7th edition of the AJCC cancer staging manual: stomach. „Ann Surg Oncol”. 17 (12), s. 3077–3079, Dec 2010. DOI: 10.1245/s10434-010-1362-z. PMID: 20882416. 
  • D. Shin, S.S. Park. Clinical importance and surgical decision-making regarding proximal resection margin for gastric cancer. „World J Gastrointest Oncol”. 5 (1), s. 4–11, Jan 2013. DOI: 10.4251/wjgo.v5.i1.4. PMID: 23738049. 
  • R.C. Martin, D.P. Jaques, M.F. Brennan, M. Karpeh. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. „Ann Surg”. 236 (2), s. 159–165, Aug 2002. DOI: 10.1097/01.SLA.0000022023.28027.5C. PMID: 12170020. 
  • W. Yu, G.S. Choi, H.Y. Chung. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. „Br J Surg”. 93 (5), s. 559–563, May 2006. DOI: 10.1002/bjs.5353. PMID: 16607678. 
  • L. Jiang, K.H. Yang, Y. Chen, Q.L. Guan i inni. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. „Br J Surg”. 101 (6), s. 595–604, May 2014. DOI: 10.1002/bjs.9497. PMID: 24668465. 
  • R. Seevaratnam, A. Bocicariu, R. Cardoso, A. Mahar i inni. A meta-analysis of D1 versus D2 lymph node dissection. „Gastric Cancer”. 15 Suppl 1, s. S60–69, Sep 2012. DOI: 10.1007/s10120-011-0110-9. PMID: 22138927. 
  • Y.W. Min, B.H. Min, J.H. Lee, J.J. Kim. Endoscopic treatment for early gastric cancer. „World J Gastroenterol”. 20 (16), s. 4566–4573, Apr 2014. DOI: 10.3748/wjg.v20.i16.4566. PMID: 24782609. 
  • M. Orditura, G. Galizia, V. Sforza, V. Gambardella i inni. Treatment of gastric cancer. „World J Gastroenterol”. 20 (7), s. 1635–1649, Feb 2014. DOI: 10.3748/wjg.v20.i7.1635. PMID: 24587643. 
  • J. Lian, S. Chen, Y. Zhang, F. Qiu. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. „Gastrointest Endosc”. 76 (4), s. 763–770, Oct 2012. DOI: 10.1016/j.gie.2012.06.014. PMID: 22884100. 
  • Y.M. Park, E. Cho, H.Y. Kang, J.M. Kim. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. „Surg Endosc”. 25 (8), s. 2666–2677, Aug 2011. DOI: 10.1007/s00464-011-1627-z. PMID: 21424201. 
  • I. Oda, D. Saito, M. Tada, H. Iishi i inni. A multicenter retrospective study of endoscopic resection for early gastric cancer. „Gastric Cancer”. 9 (4), s. 262–270, 2006. DOI: 10.1007/s10120-006-0389-0. PMID: 17235627. 
  • S. Hoteya, T. Iizuka, D. Kikuchi, N. Yahagi. Benefits of endoscopic submucosal dissection according to size and location of gastric neoplasm, compared with conventional mucosal resection. „J Gastroenterol Hepatol”. 24 (6), s. 1102–1106, Jun 2009. DOI: 10.1111/j.1440-1746.2009.05811.x. PMID: 19383079. 
  • T. Hirasawa, T. Gotoda, S. Miyata, Y. Kato i inni. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. „Gastric Cancer”. 12 (3), s. 148–152, 2009. DOI: 10.1007/s10120-009-0515-x. PMID: 19890694. 
  • N. Uedo, H. Iishi, M. Tatsuta, R. Ishihara i inni. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. „Gastric Cancer”. 9 (2), s. 88–92, 2006. DOI: 10.1007/s10120-005-0357-0. PMID: 16767363. 
  • R. Soetikno, T. Kaltenbach, R. Yeh, T. Gotoda. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. „J Clin Oncol”. 23 (20), s. 4490–4498, Jul 2005. DOI: 10.1200/JCO.2005.19.935. PMID: 16002839. 
  • Y.I. Kim, I.J. Choi. Endoscopic management of tumor bleeding from inoperable gastric cancer. „Clin Endosc”. 48 (2), s. 121–127, Mar 2015. DOI: 10.5946/ce.2015.48.2.121. PMID: 25844339. 
  • D. Cunningham, W.H. Allum, S.P. Stenning, J.N. Thompson i inni. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. „N Engl J Med”. 355 (1), s. 11–20, Jul 2006. DOI: 10.1056/NEJMoa055531. PMID: 16822992. 
  • M. Ychou, V. Boige, J.P. Pignon, T. Conroy i inni. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. „J Clin Oncol”. 29 (13), s. 1715–1721, May 2011. DOI: 10.1200/JCO.2010.33.0597. PMID: 21444866. 
  • D. Cunningham, N. Starling, S. Rao, T. Iveson i inni. Capecitabine and oxaliplatin for advanced esophagogastric cancer. „N Engl J Med”. 358 (1), s. 36–46, Jan 2008. DOI: 10.1056/NEJMoa073149. PMID: 18172173. 
  • S. Sakuramoto, M. Sasako, T. Yamaguchi, T. Kinoshita i inni. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. „N Engl J Med”. 357 (18), s. 1810–1820, Nov 2007. DOI: 10.1056/NEJMoa072252. PMID: 17978289. 
  • Y.J. Bang, Y.W. Kim, H.K. Yang, H.C. Chung i inni. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. „Lancet”. 379 (9813), s. 315–321, Jan 2012. DOI: 10.1016/S0140-6736(11)61873-4. PMID: 22226517. 
  • V. Valentini, F. Cellini, B.D. Minsky, G.C. Mattiucci i inni. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. „Radiother Oncol”. 92 (2), s. 176–183, Aug 2009. DOI: 10.1016/j.radonc.2009.06.014. PMID: 19586672. 
  • F. Fiorica, F. Cartei, M. Enea, A. Licata i inni. The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. „Cancer Treat Rev”. 33 (8), s. 729–740, Dec 2007. DOI: 10.1016/j.ctrv.2007.08.005. PMID: 17935888. 
  • S.R. Smalley, J.K. Benedetti, D.G. Haller, S.A. Hundahl i inni. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. „J Clin Oncol”. 30 (19), s. 2327–2333, Jul 2012. DOI: 10.1200/JCO.2011.36.7136. PMID: 22585691. 
  • J. Lee, do H. Lim, S. Kim, S.H. Park i inni. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. „J Clin Oncol”. 30 (3), s. 268–273, Jan 2012. DOI: 10.1200/JCO.2011.39.1953. PMID: 22184384. 
  • J.L. Dikken, E.P. Jansen, A. Cats, B. Bakker i inni. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. „J Clin Oncol”. 28 (14), s. 2430–2436, May 2010. DOI: 10.1200/JCO.2009.26.9654. PMID: 20368551. 
  • F. Rivera, M. Galán, J. Tabernero, A. Cervantes i inni. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. „Int J Radiat Oncol Biol Phys”. 75 (5), s. 1430–1436, Dec 2009. DOI: 10.1016/j.ijrobp.2008.12.087. PMID: 19540072. 
  • M. Stahl, M.K. Walz, M. Stuschke, N. Lehmann i inni. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. „J Clin Oncol”. 27 (6), s. 851–856, Feb 2009. DOI: 10.1200/JCO.2008.17.0506. PMID: 19139439. 
  • J.A. Ajani, K. Winter, G.S. Okawara, J.H. Donohue i inni. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. „J Clin Oncol”. 24 (24), s. 3953–3958, Aug 2006. DOI: 10.1200/JCO.2006.06.4840. PMID: 16921048. 
  • O. Kanat, B. O’Neil, S. Shahda. Targeted therapy for advanced gastric cancer: A review of current status and future prospects. „World J Gastrointest Oncol”. 7 (12), s. 401–410, Dec 2015. DOI: 10.4251/wjgo.v7.i12.401. PMID: 26690491. 
  • T. Takahashi, Y. Saikawa, Y. Kitagawa. Gastric cancer: current status of diagnosis and treatment. „Cancers (Basel)”. 5 (1), s. 48–63, 2013. DOI: 10.3390/cancers5010048. PMID: 24216698. 
  • S. Lim, B.E. Muhs, S.G. Marcus, E. Newman i inni. Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?. „J Surg Oncol”. 95 (2), s. 118–122, Feb 2007. DOI: 10.1002/jso.20328. PMID: 17262741. 
  • S.S. Brar, A.L. Mahar, L.K. Helyer, C. Swallow i inni. Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. „JAMA Surg”. 149 (1), s. 18–25, Jan 2014. DOI: 10.1001/jamasurg.2013.3959. PMID: 24225775. 
  • J.J. Jung, J.H. Cho, S. Shin, Y.M. Shim. Surgical treatment of anastomotic recurrence after gastrectomy for gastric cancer. „Korean J Thorac Cardiovasc Surg”. 47 (3), s. 269–274, Jun 2014. DOI: 10.5090/kjtcs.2014.47.3.269. PMID: 25207225. 
  • A.D. Wagner, W. Grothe, J. Haerting, G. Kleber i inni. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. „J Clin Oncol”. 24 (18), s. 2903–2909, Jun 2006. DOI: 10.1200/JCO.2005.05.0245. PMID: 16782930. 
  • A. Bilici. Treatment options in patients with metastatic gastric cancer: current status and future perspectives. „World J Gastroenterol”. 20 (14), s. 3905–3915, Apr 2014. DOI: 10.3748/wjg.v20.i14.3905. PMID: 24744580. 
  • A.D. Roth, N. Fazio, R. Stupp, S. Falk i inni. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. „J Clin Oncol”. 25 (22), s. 3217–3223, Aug 2007. DOI: 10.1200/JCO.2006.08.0135. PMID: 17664469. 
  • L. Di Lauro, P. Vici, F. Belli, S. Tomao i inni. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. „Gastric Cancer”. 17 (4), s. 718–724, Oct 2014. DOI: 10.1007/s10120-013-0321-3. PMID: 24318671. 
  • S.E. Al-Batran, J.T. Hartmann, R. Hofheinz, N. Homann i inni. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. „Ann Oncol”. 19 (11), s. 1882–1887, Nov 2008. DOI: 10.1093/annonc/mdn403. PMID: 18669868. 
  • E. Van Cutsem, C. Boni, J. Tabernero, B. Massuti i inni. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. „Ann Oncol”. 26 (1), s. 149–156, 2015. DOI: 10.1093/annonc/mdu496. PMID: 25416687. 
  • E. Van Cutsem, V.M. Moiseyenko, S. Tjulandin, A. Majlis i inni. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. „J Clin Oncol”. 24 (31), s. 4991–4997, Nov 2006. DOI: 10.1200/JCO.2006.06.8429. PMID: 17075117. 
  • Y.K. Kang, W.K. Kang, D.B. Shin, J. Chen i inni. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. „Ann Oncol”. 20 (4), s. 666–673, Apr 2009. DOI: 10.1093/annonc/mdn717. PMID: 19153121. 
  • A.F. Okines, A.R. Norman, P. McCloud, Y.K. Kang i inni. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. „Ann Oncol”. 20 (9), s. 1529–1534, Sep 2009. DOI: 10.1093/annonc/mdp047. PMID: 19474114. 
  • M. Dank, J. Zaluski, C. Barone, V. Valvere i inni. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. „Ann Oncol”. 19 (8), s. 1450–1457, Aug 2008. DOI: 10.1093/annonc/mdn166. PMID: 18558665. 
  • M. Moehler, S. Kanzler, M. Geissler, J. Raedle i inni. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. „Ann Oncol”. 21 (1), s. 71–77, Jan 2010. DOI: 10.1093/annonc/mdp269. PMID: 19605504. 
  • R. Guimbaud, C. Louvet, P. Ries, M. Ychou i inni. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. „J Clin Oncol”. 32 (31), s. 3520–3526, Nov 2014. DOI: 10.1200/JCO.2013.54.1011. PMID: 25287828. 
  • W. Koizumi, H. Narahara, T. Hara, A. Takagane i inni. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. „Lancet Oncol”. 9 (3), s. 215–221, Mar 2008. DOI: 10.1016/S1470-2045(08)70035-4. PMID: 18282805. 
  • J.A. Ajani, W. Rodriguez, G. Bodoky, V. Moiseyenko i inni. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. „J Clin Oncol”. 28 (9), s. 1547–1553, Mar 2010. DOI: 10.1200/JCO.2009.25.4706. PMID: 20159816. 
  • J.A. Ajani, M. Buyse, M. Lichinitser, V. Gorbunova i inni. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. „Eur J Cancer”. 49 (17), s. 3616–3624, Nov 2013. DOI: 10.1016/j.ejca.2013.07.003. PMID: 23899532. 
  • H.S. Kim, H.J. Kim, S.Y. Kim, T.Y. Kim i inni. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. „Ann Oncol”. 24 (11), s. 2850–2854, Nov 2013. DOI: 10.1093/annonc/mdt351. PMID: 23942775. 
  • D.H. Mi, Z. Li, K.H. Yang, N. Cao i inni. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. „Int J Hyperthermia”. 29 (2), s. 156–167, 2013. DOI: 10.3109/02656736.2013.768359. PMID: 23418917. 
  • G. Matharu, O. Tucker, D. Alderson. Systematic review of intraperitoneal chemotherapy for gastric cancer. „Br J Surg”. 98 (9), s. 1225–1235, Sep 2011. DOI: 10.1002/bjs.7586. PMID: 21644239. 
  • F. Coccolini, E. Cotte, O. Glehen, M. Lotti i inni. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. „Eur J Surg Oncol”. 40 (1), s. 12–26, Jan 2014. DOI: 10.1016/j.ejso.2013.10.019. PMID: 24290371. 
  • Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung i inni. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. „Lancet”. 376 (9742), s. 687–697, Aug 2010. DOI: 10.1016/S0140-6736(10)61121-X. PMID: 20728210. 
  • H. Wilke, K. Muro, E. Van Cutsem, S.C. Oh i inni. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. „Lancet Oncol”. 15 (11), s. 1224–1235, Oct 2014. DOI: 10.1016/S1470-2045(14)70420-6. PMID: 25240821. 
  • E. Santoro. The history of gastric cancer: legends and chronicles. „Gastric Cancer”. 8 (2), s. 71–74, 2005. DOI: 10.1007/s10120-005-0325-8. PMID: 15864712. 
  • S.H. Yan. An early history of human breast cancer: West meets East. „Chin J Cancer”. 32 (9), s. 475–477, Sep 2013. DOI: 10.5732/cjc.013.10097. PMID: 23958056. 
  • D.Y. Graham. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. „World J Gastroenterol”. 20 (18), s. 5191–5204, May 2014. DOI: 10.3748/wjg.v20.i18.5191. PMID: 24833849. 
  • M. Kurihara. Inducement of canine gastric cancer by N-ethyl-N'-nitro-N-nitrosoguanidine (ENNG). „Gastric Cancer”. 1 (2), s. 95–103, Mar 1998. DOI: 10.1007/s101209800001. PMID: 11957052. 
  • J. Robert. Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates. „Dev Comp Immunol”. 34 (9), s. 915–925, Sep 2010. DOI: 10.1016/j.dci.2010.05.011. PMID: 20553753. 

google.pl

books.google.pl

lsmuni.lt

eknygos.lsmuni.lt

mayoclinic.org

mp.pl

nejm.org

nih.gov

ncbi.nlm.nih.gov

  • T.L. Ang, K.M. Fock. Clinical epidemiology of gastric cancer. „Singapore Med J”. 55 (12), s. 621–628, Dec 2014. PMID: 25630323. 
  • A. Jemal, F. Bray, M.M. Center, J. Ferlay i inni. Global cancer statistics. „CA Cancer J Clin”. 61 (2). s. 69–90. DOI: 10.3322/caac.20107. PMID: 21296855. 
  • Z. Jin, W. Jiang, L. Wang. Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review). „Oncol Lett”. 9 (4), s. 1502–1508, Apr 2015. DOI: 10.3892/ol.2015.2959. PMID: 25788990. 
  • Y.O. Ahn, B.J. Park, K.Y. Yoo, N.K. Kim i inni. Incidence estimation of stomach cancer among Koreans. „J Korean Med Sci”. 6 (1), s. 7–14, Mar 1991. PMID: 1888453. 
  • K.D. Crew, A.I. Neugut. Epidemiology of gastric cancer. „World J Gastroenterol”. 12 (3), s. 354–362, Jan 2006. PMID: 16489633. 
  • M. Inoue, S. Tsugane. Epidemiology of gastric cancer in Japan. „Postgrad Med J”. 81 (957), s. 419–424, Jul 2005. DOI: 10.1136/pgmj.2004.029330. PMID: 15998815. 
  • A.W. Hsing, L.E. Hansson, J.K. McLaughlin, O. Nyren i inni. Pernicious anemia and subsequent cancer. A population-based cohort study. „Cancer”. 71 (3), s. 745–750, Feb 1993. PMID: 8431855. 
  • I. Aird, H.H. Bentall, J.A. Roberts. A relationship between cancer of stomach and the ABO blood groups. „Br Med J”. 1 (4814), s. 799–801, Apr 1953. PMID: 13032504. 
  • R. Stalnikowicz, J. Benbassat. Risk of gastric cancer after gastric surgery for benign disorders. „Arch Intern Med”. 150 (10), s. 2022–2026, Oct 1990. PMID: 2222087. 
  • S. Shousha, Y.A. Luqmani. Epstein-Barr virus in gastric carcinoma and adjacent normal gastric and duodenal mucosa. „J Clin Pathol”. 47 (8), s. 695–698, Aug 1994. PMID: 7962618. 
  • D.E. Thompson, K. Mabuchi, E. Ron, M. Soda i inni. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958–1987. „Radiat Res”. 137 (2 Suppl), s. S17–67, Feb 1994. PMID: 8127952. 
  • A. Raj, J.F. Mayberry, T. Podas. Occupation and gastric cancer. „Postgrad Med J”. 79 (931), s. 252–258, 2003. PMID: 12782770. 
  • N. Uemura, S. Okamoto, S. Yamamoto, N. Matsumura i inni. Helicobacter pylori infection and the development of gastric cancer. „N Engl J Med”. 345 (11), s. 784–789, Sep 2001. DOI: 10.1056/NEJMoa001999. PMID: 11556297. 
  • J. Parsonnet, G.D. Friedman, D.P. Vandersteen, Y. Chang i inni. Helicobacter pylori infection and the risk of gastric carcinoma. „N Engl J Med”. 325 (16), s. 1127–1131, Oct 1991. DOI: 10.1056/NEJM199110173251603. PMID: 1891020. 
  • D. Forman, D.G. Newell, F. Fullerton, J.W. Yarnell i inni. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. „BMJ”. 302 (6788), s. 1302–1305, Jun 1991. PMID: 2059685. 
  • A. Nomura, G.N. Stemmermann, P.H. Chyou, I. Kato i inni. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. „N Engl J Med”. 325 (16), s. 1132–1136, Oct 1991. DOI: 10.1056/NEJM199110173251604. PMID: 1891021. 
  • L.E. Hansson, L. Engstrand, O. Nyrén, D.J. Evans i inni. Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. „Gastroenterology”. 105 (4), s. 1098–1103, Oct 1993. PMID: 8405854. 
  • A. Kokkola, J. Valle, R. Haapiainen, P. Sipponen i inni. Helicobacter pylori infection in young patients with gastric carcinoma. „Scand J Gastroenterol”. 31 (7), s. 643–647, Jul 1996. PMID: 8819211. 
  • R. Barreto-Zuñiga, M. Maruyama, Y. Kato, K. Aizu i inni. Significance of Helicobacter pylori infection as a risk factor in gastric cancer: serological and histological studies. „J Gastroenterol”. 32 (3), s. 289–294, Jun 1997. PMID: 9213239. 
  • S. Miehlke, A. Hackelsberger, A. Meining, U. von Arnim i inni. Histological diagnosis of Helicobacter pylori gastritis is predictive of a high risk of gastric carcinoma. „Int J Cancer”. 73 (6), s. 837–839, Dec 1997. PMID: 9399662. 
  • P. Correa. Helicobacter pylori and gastric cancer: state of the art. „Cancer Epidemiol Biomarkers Prev”. 5 (6), s. 477–481, Jun 1996. PMID: 8781746. 
  • E.J. Kuipers, G.I. Pérez-Pérez, S.G. Meuwissen, M.J. Blaser. Helicobacter pylori and atrophic gastritis: importance of the cagA status. „J Natl Cancer Inst”. 87 (23), s. 1777–1780, Dec 1995. PMID: 7473834. 
  • J. Parsonnet, G.D. Friedman, N. Orentreich, H. Vogelman. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. „Gut”. 40 (3), s. 297–301, Mar 1997. PMID: 9135515. 
  • M.J. Blaser. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. „J Infect Dis”. 179 (6), s. 1523–1530, Jun 1999. DOI: 10.1086/314785. PMID: 10228075. 
  • L. D’Elia, G. Rossi, R. Ippolito, F.P. Cappuccio i inni. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. „Clin Nutr”. 31 (4), s. 489–498, Aug 2012. DOI: 10.1016/j.clnu.2012.01.003. PMID: 22296873. 
  • X.Q. Wang, P.D. Terry, H. Yan. Review of salt consumption and stomach cancer risk: epidemiological and biological evidence. „World J Gastroenterol”. 15 (18), s. 2204–2213, May 2009. PMID: 19437559. 
  • J.V. Joossens, M.J. Hill, P. Elliott, R. Stamler i inni. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. „Int J Epidemiol”. 25 (3), s. 494–504, Jun 1996. PMID: 8671549. 
  • M.L. McCullough, A.S. Robertson, E.J. Jacobs, A. Chao i inni. A prospective study of diet and stomach cancer mortality in United States men and women. „Cancer Epidemiol Biomarkers Prev”. 10 (11), s. 1201–1205, 2001. PMID: 11700269. 
  • M.G. Hertog, H.B. Bueno-de-Mesquita, A.M. Fehily, P.M. Sweetnam i inni. Fruit and vegetable consumption and cancer mortality in the Caerphilly Study. „Cancer Epidemiol Biomarkers Prev”. 5 (9), s. 673–677, Sep 1996. PMID: 8877056. 
  • M. Kobayashi, Y. Tsubono, S. Sasazuki, S. Sasaki i inni. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I. „Int J Cancer”. 102 (1), s. 39–44, Nov 2002. DOI: 10.1002/ijc.10659. PMID: 12353232. 
  • Y. Zhou, W. Zhuang, W. Hu, G.J. Liu i inni. Consumption of large amounts of Allium vegetables reduces risk for gastric cancer in a meta-analysis. „Gastroenterology”. 141 (1), s. 80–89, 2011. DOI: 10.1053/j.gastro.2011.03.057. PMID: 21473867. 
  • V. Guercio, C. Galeone, F. Turati, C. La Vecchia. Gastric cancer and allium vegetable intake: a critical review of the experimental and epidemiologic evidence. „Nutr Cancer”. 66 (5), s. 757–773, 2014. DOI: 10.1080/01635581.2014.904911. PMID: 24820444. 
  • F. Turati, C. Pelucchi, V. Guercio, C. La Vecchia i inni. Allium vegetable intake and gastric cancer: a case-control study and meta-analysis. „Mol Nutr Food Res”. 59 (1), s. 171–179, 2015. DOI: 10.1002/mnfr.201400496. PMID: 25215621. 
  • P. Guilford, J. Hopkins, J. Harraway, M. McLeod i inni. E-cadherin germline mutations in familial gastric cancer. „Nature”. 392 (6674), s. 402–405, Mar 1998. DOI: 10.1038/32918. PMID: 9537325. 
  • R.C. Fitzgerald, C. Caldas. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. „Gut”. 53 (6). s. 775–778 rok = 2004. PMID: 15138199. 
  • R.C. Fitzgerald, R. Hardwick, D. Huntsman, F. Carneiro i inni. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. „J Med Genet”. 47 (7), s. 436–444, 2010. DOI: 10.1136/jmg.2009.074237. PMID: 20591882. 
  • S. Masciari, N. Larsson, J. Senz, N. Boyd i inni. Germline E-cadherin mutations in familial lobular breast cancer. „J Med Genet”. 44 (11), s. 726–731, Nov 2007. DOI: 10.1136/jmg.2007.051268. PMID: 17660459. 
  • W. Cichy, B. Klincewicz, A. Plawski. Juvenile polyposis syndrome. „Arch Med Sci”. 10 (3), s. 570–577, Jun 2014. DOI: 10.5114/aoms.2014.43750. PMID: 25097590. 
  • A. Hemminki, D. Markie, I. Tomlinson, E. Avizienyte i inni. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. „Nature”. 391 (6663), s. 184–187, Jan 1998. DOI: 10.1038/34432. PMID: 9428765. 
  • F.M. Giardiello, J.D. Brensinger, A.C. Tersmette, S.N. Goodman i inni. Very high risk of cancer in familial Peutz-Jeghers syndrome. „Gastroenterology”. 119 (6), s. 1447–1453, Dec 2000. PMID: 11113065. 
  • C.A. González, G. Pera, A. Agudo, D. Palli i inni. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). „Int J Cancer”. 107 (4), s. 629–634, Nov 2003. DOI: 10.1002/ijc.11426. PMID: 14520702. 
  • A. Chao, M.J. Thun, S.J. Henley, E.J. Jacobs i inni. Cigarette smoking, use of other tobacco products and stomach cancer mortality in US adults: The Cancer Prevention Study II. „Int J Cancer”. 101 (4), s. 380–389, Oct 2002. DOI: 10.1002/ijc.10614. PMID: 12209964. 
  • Y. Koizumi, Y. Tsubono, N. Nakaya, S. Kuriyama i inni. Cigarette smoking and the risk of gastric cancer: a pooled analysis of two prospective studies in Japan. „Int J Cancer”. 112 (6), s. 1049–1055, Dec 2004. DOI: 10.1002/ijc.20518. PMID: 15386347. 
  • W.H. Chow, W.J. Blot, T.L. Vaughan, H.A. Risch i inni. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. „J Natl Cancer Inst”. 90 (2), s. 150–155, Jan 1998. PMID: 9450576. 
  • V. Pasechnikov, S. Chukov, E. Fedorov, I. Kikuste i inni. Gastric cancer: prevention, screening and early diagnosis. „World J Gastroenterol”. 20 (38), s. 13842–13862, Oct 2014. DOI: 10.3748/wjg.v20.i38.13842. PMID: 25320521. 
  • T. Waddell, M. Verheij, W. Allum, D. Cunningham i inni. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. „Ann Oncol”. 24 Suppl 6, s. vi57–63, Oct 2013. DOI: 10.1093/annonc/mdt344. PMID: 24078663. 
  • F. O’Connor, M. Buckley, C. O’Morain. Helicobacter pylori: the cancer link. „J R Soc Med”. 89 (12), s. 674–678, Dec 1996. PMID: 9014876. 
  • M. Asahi, T. Azuma, S. Ito, Y. Ito i inni. Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. „J Exp Med”. 191 (4), s. 593–602, Feb 2000. PMID: 10684851. PMCID: PMC2195829. 
  • E.D. Segal, J. Cha, J. Lo, S. Falkow i inni. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. „Proc Natl Acad Sci U S A”. 96 (25), s. 14559–14564, Dec 1999. PMID: 10588744. 
  • E.D. Segal, C. Lange, A. Covacci, L.S. Tompkins i inni. Induction of host signal transduction pathways by Helicobacter pylori. „Proc Natl Acad Sci U S A”. 94 (14), s. 7595–7599, Jul 1997. PMID: 9207137. 
  • T. de Figueiredo Soares, D.M. de Magalhães Queiroz, E.N. Mendes, G.A. Rocha i inni. The interrelationship between Helicobacter pylori vacuolating cytotoxin and gastric carcinoma. „Am J Gastroenterol”. 93 (10), s. 1841–1847, Oct 1998. DOI: 10.1111/j.1572-0241.1998.533_d.x. PMID: 9772042. 
  • Z.W. Zhang, S.E. Patchett, D. Perrett, P.H. Katelaris i inni. The relation between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity in the human stomach. „Gut”. 43 (3), s. 322–326, Sep 1998. PMID: 9863475. 
  • J.A. Simon, E.S. Hudes, G.I. Perez-Perez. Relation of serum ascorbic acid to Helicobacter pylori serology in US adults: the Third National Health and Nutrition Examination Survey. „J Am Coll Nutr”. 22 (4), s. 283–289, Aug 2003. PMID: 12897042. 
  • R. Fiocca, O. Luinetti, L. Villani, A.M. Chiaravalli i inni. Epithelial cytotoxicity, immune responses, and inflammatory components of Helicobacter pylori gastritis. „Scand J Gastroenterol Suppl”. 205, s. 11–21, 1994. PMID: 7863237. 
  • A. Yanai, Y. Hirata, Y. Mitsuno, S. Maeda i inni. Helicobacter pylori induces antiapoptosis through buclear factor-kappaB activation. „J Infect Dis”. 188 (11), s. 1741–1751, Dec 2003. DOI: 10.1086/379629. PMID: 14639546. 
  • A. Zullo, C. Hassan, L. Ridola, A. Repici i inni. Gastric MALT lymphoma: old and new insights. „Ann Gastroenterol”. 27 (1), s. 27–33, 2014. PMID: 24714739. 
  • B. Hu, N. El Hajj, S. Sittler, N. Lammert i inni. Gastric cancer: Classification, histology and application of molecular pathology. „J Gastrointest Oncol”. 3 (3), s. 251–261, Sep 2012. DOI: 10.3978/j.issn.2078-6891.2012.021. PMID: 22943016. 
  • P. Lauren. the two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. „Acta Pathol Microbiol Scand”. 64, s. 31–49, 1965. PMID: 14320675. 
  • S. Kaneko, T. Yoshimura. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975–1989. „Br J Cancer”. 84 (3), s. 400–405, Feb 2001. DOI: 10.1054/bjoc.2000.1602. PMID: 11161407. 
  • J. Parsonnet, D. Vandersteen, J. Goates, R.K. Sibley i inni. Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. „J Natl Cancer Inst”. 83 (9), s. 640–643, May 1991. PMID: 2023282. 
  • W. Polkowski, J.W. van Sandick, G.J. Offerhaus, F.J. ten Kate i inni. Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. „Ann Surg Oncol”. 6 (3). s. 290–297. PMID: 10340889. 
  • M. Qiu, Y. Zhou, X. Zhang, Z. Wang i inni. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. „BMC Cancer”. 14, s. 823, 2014. DOI: 10.1186/1471-2407-14-823. PMID: 25380654. 
  • C.C. Yu, D.A. Levison, J.A. Dunn, L.C. Ward i inni. Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. „Br J Cancer”. 71 (5), s. 1106–1110, May 1995. PMID: 7734309. 
  • S. Mönig, S.E. Baldus, P.H. Collet, T.K. Zirbes i inni. Histological grading in gastric cancer by Goseki classification: correlation with histopathological subtypes and prognosis. „Anticancer Res”. 21 (1B). s. 617–620. PMID: 11299815. 
  • P. Garnier, P. Vielh, B. Asselain, J.C. Durand i inni. Prognostic value of the Lauren and Ming classifications in gastric adenocarcinoma. Multidimensional analysis. „Gastroenterol Clin Biol”. 12 (6–7). s. 553–558. PMID: 3417082. 
  • F. Berlth, E. Bollschweiler, U. Drebber, A.H. Hoelscher i inni. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. „World J Gastroenterol”. 20 (19), s. 5679–5684, May 2014. DOI: 10.3748/wjg.v20.i19.5679. PMID: 24914328. 
  • J.R. Siewert, H.J. Stein. Classification of adenocarcinoma of the oesophagogastric junction. „Br J Surg”. 85 (11), s. 1457–1459, Nov 1998. DOI: 10.1046/j.1365-2168.1998.00940.x. PMID: 9823902. 
  • J. Fujisaki, T. Nakajima, T. Hirasawa, Y. Yamamoto i inni. Natural history of gastric cancer-a case followed up for eight years: early to advanced gastric cancer. „Clin J Gastroenterol”. 5 (5), s. 351–354, Oct 2012. DOI: 10.1007/s12328-012-0325-2. PMID: 23087768. 
  • A. Axon. Natural history of early gastric cancer. „Gut”. 47 (5), s. 609, Nov 2000. PMID: 11034572. 
  • H. Tsukuma, A. Oshima, H. Narahara, T. Morii. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. „Gut”. 47 (5), s. 618–621, Nov 2000. PMID: 11034575. 
  • K. Maruyama, P. Gunvén, K. Okabayashi, M. Sasako i inni. Lymph node metastases of gastric cancer. General pattern in 1931 patients. „Ann Surg”. 210 (5), s. 596–602, Nov 1989. PMID: 2818028. 
  • J.T. Hallinan, S.K. Venkatesh. Gastric carcinoma: imaging diagnosis, staging and assessment of treatment response. „Cancer Imaging”. 13, s. 212–227, 2013. DOI: 10.1102/1470-7330.2013.0023. PMID: 23722535. 
  • B.J. Dicken, D.L. Bigam, C. Cass, J.R. Mackey i inni. Gastric adenocarcinoma: review and considerations for future directions. „Ann Surg”. 241 (1), s. 27–39, Jan 2005. PMID: 15621988. 
  • O. Hosokawa, S. Tsuda, E. Kidani, K. Watanabe i inni. Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. „Endoscopy”. 30 (8), s. 669–674, Oct 1998. DOI: 10.1055/s-2007-1001386. PMID: 9865554. 
  • X.M. Meng, Y. Zhou, T. Dang, X.Y. Tian i inni. Magnifying chromoendoscopy combined with immunohistochemical staining for early diagnosis of gastric cancer. „World J Gastroenterol”. 19 (3), s. 404–410, Jan 2013. DOI: 10.3748/wjg.v19.i3.404. PMID: 23372365. 
  • K. Yao. The endoscopic diagnosis of early gastric cancer. „Ann Gastroenterol”. 26 (1), s. 11–22, 2013. PMID: 24714327. 
  • D. Bentrem, H. Gerdes, L. Tang, M. Brennan i inni. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. „Ann Surg Oncol”. 14 (6), s. 1853–1859, Jun 2007. DOI: 10.1245/s10434-006-9037-5. PMID: 17357856. 
  • M.A. Mekky, K. Yamao, A. Sawaki, N. Mizuno i inni. Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors. „Gastrointest Endosc”. 71 (6), s. 913–919, May 2010. DOI: 10.1016/j.gie.2009.11.044. PMID: 20226456. 
  • C.Y. Chen, J.S. Hsu, D.C. Wu, W.Y. Kang i inni. Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results. „Radiology”. 242 (2), s. 472–482, Feb 2007. DOI: 10.1148/radiol.2422051557. PMID: 17255419. 
  • H.J. Kim, A.Y. Kim, S.T. Oh, J.S. Kim i inni. Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning. „Radiology”. 236 (3), s. 879–885, Sep 2005. DOI: 10.1148/radiol.2363041101. PMID: 16020558. 
  • D.M. Yang, H.C. Kim, W. Jin, C.W. Ryu i inni. 64 multidetector-row computed tomography for preoperative evaluation of gastric cancer: histological correlation. „J Comput Assist Tomogr”. 31 (1). s. 98–103. DOI: 10.1097/01.rct.0000234072.16209.ab. PMID: 17259840. 
  • B.B. Chen, P.C. Liang, K.L. Liu, J.K. Hsiao i inni. Preoperative diagnosis of gastric tumors by three-dimensional multidetector row ct and double contrast barium meal study: correlation with surgical and histologic results. „J Formos Med Assoc”. 106 (11), s. 943–952, Nov 2007. DOI: 10.1016/S0929-6646(08)60065-0. PMID: 18063516. 
  • S.J. Wakelin, C. Deans, T.J. Crofts, P.L. Allan i inni. A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophago-gastric carcinoma. „Eur J Radiol”. 41 (2), s. 161–167, Feb 2002. PMID: 11809546. 
  • M. Yun. Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT. „J Gastric Cancer”. 14 (1), s. 1–6, Mar 2014. DOI: 10.5230/jgc.2014.14.1.1. PMID: 24765531. 
  • C.X. Wu, Z.H. Zhu. Diagnosis and evaluation of gastric cancer by positron emission tomography. „World J Gastroenterol”. 20 (16), s. 4574–4585, Apr 2014. DOI: 10.3748/wjg.v20.i16.4574. PMID: 24782610. 
  • A.E. Dassen, D.J. Lips, C.J. Hoekstra, J.F. Pruijt i inni. FDG-PET has no definite role in preoperative imaging in gastric cancer. „Eur J Surg Oncol”. 35 (5), s. 449–455, May 2009. DOI: 10.1016/j.ejso.2008.11.010. PMID: 19147324. 
  • H. Shimada, S. Okazumi, M. Koyama, K. Murakami. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of ¹⁸F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. „Gastric Cancer”. 14 (1), s. 13–21, Mar 2011. DOI: 10.1007/s10120-011-0017-5. PMID: 21331531. 
  • H. Hur, S.H. Kim, W. Kim, K.Y. Song i inni. The efficacy of preoperative PET/CT for prediction of curability in surgery for locally advanced gastric carcinoma. „World J Surg Oncol”. 8, s. 86, 2010. DOI: 10.1186/1477-7819-8-86. PMID: 20932345. 
  • J.S. Lim, M.J. Kim, M.J. Yun, Y.T. Oh i inni. Comparison of CT and 18F-FDG pet for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma. „Korean J Radiol”. 7 (4). s. 249–256. PMID: 17143028. 
  • E. Smyth, H. Schöder, V.E. Strong, M. Capanu i inni. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. „Cancer”. 118 (22), s. 5481–5488, Nov 2012. DOI: 10.1002/cncr.27550. PMID: 22549558. 
  • K. Mukai, Y. Ishida, K. Okajima, H. Isozaki i inni. Usefulness of preoperative FDG-PET for detection of gastric cancer. „Gastric Cancer”. 9 (3), s. 192–196, 2006. DOI: 10.1007/s10120-006-0374-7. PMID: 16952037. 
  • M. Tanner, M. Hollmén, T.T. Junttila, A.I. Kapanen i inni. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. „Ann Oncol”. 16 (2), s. 273–278, Feb 2005. DOI: 10.1093/annonc/mdi064. PMID: 15668283. 
  • B. Yan, E.X. Yau, S.S. Bte Omar, C.W. Ong i inni. A study of HER2 gene amplification and protein expression in gastric cancer. „J Clin Pathol”. 63 (9), s. 839–842, Sep 2010. DOI: 10.1136/jcp.2010.076570. PMID: 20696687. 
  • C. Gómez-Martin, E. Garralda, M.J. Echarri, A. Ballesteros i inni. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. „J Clin Pathol”. 65 (8), s. 751–757, Aug 2012. DOI: 10.1136/jclinpath-2012-200774. PMID: 22569536. 
  • J.T. Jørgensen, M. Hersom. HER2 as a Prognostic Marker in Gastric Cancer – A Systematic Analysis of Data from the Literature. „J Cancer”. 3, s. 137–144, 2012. DOI: 10.7150/jca.4090. PMID: 22481979. 
  • T.C. Chua, N.D. Merrett. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. „Int J Cancer”. 130 (12), s. 2845–2856, Jun 2012. DOI: 10.1002/ijc.26292. PMID: 21780108. 
  • Y. Nakane, S. Okamura, K. Akehira, T. Boku i inni. Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. „Cancer”. 73 (11), s. 2703–2708, Jun 1994. PMID: 8194009. 
  • E. Ucar, E. Semerci, H. Ustun, T. Yetim i inni. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. „Adv Ther”. 25 (10), s. 1075–1084, Oct 2008. DOI: 10.1007/s12325-008-0100-4. PMID: 18821070. 
  • D. Marrelli, F. Roviello, A. De Stefano, M. Farnetani i inni. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. „Oncology”. 57 (1), s. 55–62, Jul 1999. DOI: 10.1159/000012001. PMID: 10394126. 
  • M. Kochi, M. Fujii, N. Kanamori, T. Kaiga i inni. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. „Gastric Cancer”. 3 (4), s. 177–186, Dec 2000. PMID: 11984734. 
  • K. Deng, L. Yang, B. Hu, H. Wu i inni. The Prognostic Significance of Pretreatment Serum CEA Levels in Gastric Cancer: A Meta-Analysis Including 14651 Patients. „PLoS One”. 10 (4), s. e0124151, 2015. DOI: 10.1371/journal.pone.0124151. PMID: 25879931. 
  • N. Shimizu, T. Wakatsuki, A. Murakami, H. Yoshioka i inni. Carcinoembryonic antigen in gastric cancer patients. „Oncology”. 44 (4), s. 240–244, 1987. PMID: 3614814. 
  • E. Polat, U. Duman, M. Duman, K. Derya Peker i inni. Preoperative serum tumor marker levels in gastric cancer. „Pak J Med Sci”. 30 (1), s. 145–149, Jan 2014. DOI: 10.12669/pjms.301.3968. PMID: 24639849. 
  • E. Dilege, M. Mihmanli, U. Demir, K. Ozer i inni. Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer. „Hepatogastroenterology”. 57 (99–100). s. 674–677. PMID: 20698248. 
  • M. Ychou, J. Duffour, A. Kramar, S. Gourgou i inni. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. „Dis Markers”. 16 (3–4), s. 105–110, 2000. PMID: 11381189. 
  • M.J. Gaspar, I. Arribas, M.C. Coca, M. Díez-Alonso. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. „Tumour Biol”. 22 (5). s. 318–322. DOI: 10.1159/000050633. PMID: 11553862. 
  • A. Sehdev, D.V. Catenacci. Gastroesophageal cancer: focus on epidemiology, classification, and staging. „Discov Med”. 16 (87), s. 103–111, Sep 2013. PMID: 23998446. 
  • T. Tsendsuren, S.M. Jun, X.H. Mian. Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer. „World J Gastroenterol”. 12 (1), s. 43–47, Jan 2006. PMID: 16440415. 
  • J. Chen, J.H. Cheong, M.J. Yun, J. Kim i inni. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. „Cancer”. 103 (11), s. 2383–2390, Jun 2005. DOI: 10.1002/cncr.21074. PMID: 15856477. 
  • S. Msika, A.M. Benhamiche, J.L. Jouve, P. Rat i inni. Prognostic factors after curative resection for gastric cancer. A population-based study. „Eur J Cancer”. 36 (3), s. 390–396, Feb 2000. PMID: 10708942. 
  • J.R. Siewert, K. Böttcher, H.J. Stein, J.D. Roder. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. „Ann Surg”. 228 (4), s. 449–461, Oct 1998. PMID: 9790335. 
  • T. Yokota, Y. Kunii, S. Teshima, Y. Yamada i inni. Significant prognostic factors in patients with early gastric cancer. „Int Surg”. 85 (4). s. 286–290. PMID: 11589593. 
  • Y. Adachi, N. Shiraishi, T. Suematsu, A. Shiromizu i inni. Most important lymph node information in gastric cancer: multivariate prognostic study. „Ann Surg Oncol”. 7 (7), s. 503–507, Aug 2000. PMID: 10947018. 
  • K. Borch, B. Jönsson, E. Tarpila, T. Franzén i inni. Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. „Br J Surg”. 87 (5), s. 618–626, May 2000. DOI: 10.1046/j.1365-2168.2000.01425.x. PMID: 10792320. 
  • J. Pinto-De-Sousa, L. David, M. Seixas, A. Pimenta. Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. „Dig Surg”. 18 (2), s. 102–110, 2001. DOI: 10.1159/000050109. PMID: 11351154. 
  • H.G. Hass, U. Smith, C. Jäger, M. Schäffer i inni. Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren’s): single-center experience of 160 cases. „Onkologie”. 34 (12), s. 682–686, 2011. DOI: 10.1159/000334545. PMID: 22156447. 
  • K. Yasuda, Y. Adachi, N. Shiraishi, S. Maeo i inni. Papillary adenocarcinoma of the stomach. „Gastric Cancer”. 3 (1), s. 33–38, Aug 2000. PMID: 11984707. 
  • H.C. Zheng, Y.S. Zheng, P. Xia, X.Y. Xu i inni. The pathobiological behaviors and prognosis associated with Japanese gastric adenocarcinomas of pure WHO histological subtypes. „Histol Histopathol”. 25 (4), s. 445–452, Apr 2010. PMID: 20183797. 
  • T. Yokota, Y. Kunii, S. Teshima, Y. Yamada i inni. Significant prognostic factors in patients with node-negative gastric cancer. „Int Surg”. 84 (4). s. 331–336. PMID: 10667813. 
  • D.A. Kooby, A. Suriawinata, D.S. Klimstra, M.F. Brennan i inni. Biologic predictors of survival in node-negative gastric cancer. „Ann Surg”. 237 (6), s. 828–835; discussion 835–783, Jun 2003. DOI: 10.1097/01.SLA.0000072260.77776.39. PMID: 12796579. 
  • K. Washington. 7th edition of the AJCC cancer staging manual: stomach. „Ann Surg Oncol”. 17 (12), s. 3077–3079, Dec 2010. DOI: 10.1245/s10434-010-1362-z. PMID: 20882416. 
  • D. Shin, S.S. Park. Clinical importance and surgical decision-making regarding proximal resection margin for gastric cancer. „World J Gastrointest Oncol”. 5 (1), s. 4–11, Jan 2013. DOI: 10.4251/wjgo.v5.i1.4. PMID: 23738049. 
  • F. Bozzetti, E. Marubini, G. Bonfanti, R. Miceli i inni. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. „Ann Surg”. 230 (2), s. 170–178, Aug 1999. PMID: 10450730. 
  • René G Holzheimer, John A Mannick: Surgical Treatment Evidence-Based and Problem-Oriented. 2011. ISBN 3-88603-714-2.
  • L.E. Harrison, M.S. Karpeh, M.F. Brennan. Total gastrectomy is not necessary for proximal gastric cancer. „Surgery”. 123 (2), s. 127–130, Feb 1998. PMID: 9481396. 
  • R.C. Martin, D.P. Jaques, M.F. Brennan, M. Karpeh. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. „Ann Surg”. 236 (2), s. 159–165, Aug 2002. DOI: 10.1097/01.SLA.0000022023.28027.5C. PMID: 12170020. 
  • R. Swan, T.J. Miner. Current role of surgical therapy in gastric cancer. „World J Gastroenterol”. 12 (3), s. 372–379, Jan 2006. PMID: 16489635. 
  • Y. Kasakura, M. Fujii, F. Mochizuki, M. Kochi i inni. Is there a benefit of pancreaticosplenectomy with gastrectomy for advanced gastric cancer?. „Am J Surg”. 179 (3), s. 237–242, Mar 2000. PMID: 10827328. 
  • Y. Nakane, S. Okumura, K. Akehira, S. Okamura i inni. Jejunal pouch reconstruction after total gastrectomy for cancer. A randomized controlled trial. „Ann Surg”. 222 (1), s. 27–35, Jul 1995. PMID: 7618964. 
  • J.A. Ajani, R.J. Mayer, D.M. Ota, G.D. Steele i inni. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. „J Natl Cancer Inst”. 85 (22), s. 1839–1844, Nov 1993. PMID: 8230264. 
  • L. Leichman, H. Silberman, C.G. Leichman, C.P. Spears i inni. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. „J Clin Oncol”. 10 (12), s. 1933–1942, Dec 1992. PMID: 1453207. 
  • W. Yu, G.S. Choi, H.Y. Chung. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. „Br J Surg”. 93 (5), s. 559–563, May 2006. DOI: 10.1002/bjs.5353. PMID: 16607678. 
  • L. Jiang, K.H. Yang, Y. Chen, Q.L. Guan i inni. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. „Br J Surg”. 101 (6), s. 595–604, May 2014. DOI: 10.1002/bjs.9497. PMID: 24668465. 
  • R. Seevaratnam, A. Bocicariu, R. Cardoso, A. Mahar i inni. A meta-analysis of D1 versus D2 lymph node dissection. „Gastric Cancer”. 15 Suppl 1, s. S60–69, Sep 2012. DOI: 10.1007/s10120-011-0110-9. PMID: 22138927. 
  • Y.W. Min, B.H. Min, J.H. Lee, J.J. Kim. Endoscopic treatment for early gastric cancer. „World J Gastroenterol”. 20 (16), s. 4566–4573, Apr 2014. DOI: 10.3748/wjg.v20.i16.4566. PMID: 24782609. 
  • M. Orditura, G. Galizia, V. Sforza, V. Gambardella i inni. Treatment of gastric cancer. „World J Gastroenterol”. 20 (7), s. 1635–1649, Feb 2014. DOI: 10.3748/wjg.v20.i7.1635. PMID: 24587643. 
  • J. Lian, S. Chen, Y. Zhang, F. Qiu. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. „Gastrointest Endosc”. 76 (4), s. 763–770, Oct 2012. DOI: 10.1016/j.gie.2012.06.014. PMID: 22884100. 
  • Y.M. Park, E. Cho, H.Y. Kang, J.M. Kim. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. „Surg Endosc”. 25 (8), s. 2666–2677, Aug 2011. DOI: 10.1007/s00464-011-1627-z. PMID: 21424201. 
  • I. Oda, D. Saito, M. Tada, H. Iishi i inni. A multicenter retrospective study of endoscopic resection for early gastric cancer. „Gastric Cancer”. 9 (4), s. 262–270, 2006. DOI: 10.1007/s10120-006-0389-0. PMID: 17235627. 
  • S. Hoteya, T. Iizuka, D. Kikuchi, N. Yahagi. Benefits of endoscopic submucosal dissection according to size and location of gastric neoplasm, compared with conventional mucosal resection. „J Gastroenterol Hepatol”. 24 (6), s. 1102–1106, Jun 2009. DOI: 10.1111/j.1440-1746.2009.05811.x. PMID: 19383079. 
  • T. Hirasawa, T. Gotoda, S. Miyata, Y. Kato i inni. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. „Gastric Cancer”. 12 (3), s. 148–152, 2009. DOI: 10.1007/s10120-009-0515-x. PMID: 19890694. 
  • N. Uedo, H. Iishi, M. Tatsuta, R. Ishihara i inni. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. „Gastric Cancer”. 9 (2), s. 88–92, 2006. DOI: 10.1007/s10120-005-0357-0. PMID: 16767363. 
  • H. Ono, H. Kondo, T. Gotoda, K. Shirao i inni. Endoscopic mucosal resection for treatment of early gastric cancer. „Gut”. 48 (2), s. 225–229, Feb 2001. PMID: 11156645. 
  • R. Soetikno, T. Kaltenbach, R. Yeh, T. Gotoda. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. „J Clin Oncol”. 23 (20), s. 4490–4498, Jul 2005. DOI: 10.1200/JCO.2005.19.935. PMID: 16002839. 
  • Y.I. Kim, I.J. Choi. Endoscopic management of tumor bleeding from inoperable gastric cancer. „Clin Endosc”. 48 (2), s. 121–127, Mar 2015. DOI: 10.5946/ce.2015.48.2.121. PMID: 25844339. 
  • D. Cunningham, W.H. Allum, S.P. Stenning, J.N. Thompson i inni. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. „N Engl J Med”. 355 (1), s. 11–20, Jul 2006. DOI: 10.1056/NEJMoa055531. PMID: 16822992. 
  • M. Ychou, V. Boige, J.P. Pignon, T. Conroy i inni. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. „J Clin Oncol”. 29 (13), s. 1715–1721, May 2011. DOI: 10.1200/JCO.2010.33.0597. PMID: 21444866. 
  • D. Cunningham, N. Starling, S. Rao, T. Iveson i inni. Capecitabine and oxaliplatin for advanced esophagogastric cancer. „N Engl J Med”. 358 (1), s. 36–46, Jan 2008. DOI: 10.1056/NEJMoa073149. PMID: 18172173. 
  • S. Sakuramoto, M. Sasako, T. Yamaguchi, T. Kinoshita i inni. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. „N Engl J Med”. 357 (18), s. 1810–1820, Nov 2007. DOI: 10.1056/NEJMoa072252. PMID: 17978289. 
  • Y.J. Bang, Y.W. Kim, H.K. Yang, H.C. Chung i inni. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. „Lancet”. 379 (9813), s. 315–321, Jan 2012. DOI: 10.1016/S0140-6736(11)61873-4. PMID: 22226517. 
  • V. Valentini, F. Cellini, B.D. Minsky, G.C. Mattiucci i inni. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. „Radiother Oncol”. 92 (2), s. 176–183, Aug 2009. DOI: 10.1016/j.radonc.2009.06.014. PMID: 19586672. 
  • F. Fiorica, F. Cartei, M. Enea, A. Licata i inni. The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. „Cancer Treat Rev”. 33 (8), s. 729–740, Dec 2007. DOI: 10.1016/j.ctrv.2007.08.005. PMID: 17935888. 
  • S.R. Smalley, J.K. Benedetti, D.G. Haller, S.A. Hundahl i inni. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. „J Clin Oncol”. 30 (19), s. 2327–2333, Jul 2012. DOI: 10.1200/JCO.2011.36.7136. PMID: 22585691. 
  • H.S. Lee, Y. Choi, W.J. Hur, H.J. Kim i inni. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. „World J Gastroenterol”. 12 (4), s. 603–607, Jan 2006. PMID: 16489675. 
  • J. Lee, do H. Lim, S. Kim, S.H. Park i inni. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. „J Clin Oncol”. 30 (3), s. 268–273, Jan 2012. DOI: 10.1200/JCO.2011.39.1953. PMID: 22184384. 
  • J.L. Dikken, E.P. Jansen, A. Cats, B. Bakker i inni. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. „J Clin Oncol”. 28 (14), s. 2430–2436, May 2010. DOI: 10.1200/JCO.2009.26.9654. PMID: 20368551. 
  • F. Rivera, M. Galán, J. Tabernero, A. Cervantes i inni. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. „Int J Radiat Oncol Biol Phys”. 75 (5), s. 1430–1436, Dec 2009. DOI: 10.1016/j.ijrobp.2008.12.087. PMID: 19540072. 
  • M. Stahl, M.K. Walz, M. Stuschke, N. Lehmann i inni. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. „J Clin Oncol”. 27 (6), s. 851–856, Feb 2009. DOI: 10.1200/JCO.2008.17.0506. PMID: 19139439. 
  • J.A. Ajani, K. Winter, G.S. Okawara, J.H. Donohue i inni. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. „J Clin Oncol”. 24 (24), s. 3953–3958, Aug 2006. DOI: 10.1200/JCO.2006.06.4840. PMID: 16921048. 
  • A.M. Lowy, B.W. Feig, N. Janjan, T.A. Rich i inni. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. „Ann Surg Oncol”. 8 (6), s. 519–524, Jul 2001. PMID: 11456051. 
  • O. Kanat, B. O’Neil, S. Shahda. Targeted therapy for advanced gastric cancer: A review of current status and future prospects. „World J Gastrointest Oncol”. 7 (12), s. 401–410, Dec 2015. DOI: 10.4251/wjgo.v7.i12.401. PMID: 26690491. 
  • T. Takahashi, Y. Saikawa, Y. Kitagawa. Gastric cancer: current status of diagnosis and treatment. „Cancers (Basel)”. 5 (1), s. 48–63, 2013. DOI: 10.3390/cancers5010048. PMID: 24216698. 
  • S. Lim, B.E. Muhs, S.G. Marcus, E. Newman i inni. Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?. „J Surg Oncol”. 95 (2), s. 118–122, Feb 2007. DOI: 10.1002/jso.20328. PMID: 17262741. 
  • S.S. Brar, A.L. Mahar, L.K. Helyer, C. Swallow i inni. Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. „JAMA Surg”. 149 (1), s. 18–25, Jan 2014. DOI: 10.1001/jamasurg.2013.3959. PMID: 24225775. 
  • A. Nashimoto, H. Yabusaki, A. Matsuki, M. Aizawa. Surgical treatment for curable and incurable recurrent gastric cancer. „Gan To Kagaku Ryoho”. 40 (8), s. 971–975, Aug 2013. PMID: 23986037. 
  • J.J. Jung, J.H. Cho, S. Shin, Y.M. Shim. Surgical treatment of anastomotic recurrence after gastrectomy for gastric cancer. „Korean J Thorac Cardiovasc Surg”. 47 (3), s. 269–274, Jun 2014. DOI: 10.5090/kjtcs.2014.47.3.269. PMID: 25207225. 
  • A.D. Wagner, W. Grothe, J. Haerting, G. Kleber i inni. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. „J Clin Oncol”. 24 (18), s. 2903–2909, Jun 2006. DOI: 10.1200/JCO.2005.05.0245. PMID: 16782930. 
  • A. Bilici. Treatment options in patients with metastatic gastric cancer: current status and future perspectives. „World J Gastroenterol”. 20 (14), s. 3905–3915, Apr 2014. DOI: 10.3748/wjg.v20.i14.3905. PMID: 24744580. 
  • A.D. Roth, N. Fazio, R. Stupp, S. Falk i inni. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. „J Clin Oncol”. 25 (22), s. 3217–3223, Aug 2007. DOI: 10.1200/JCO.2006.08.0135. PMID: 17664469. 
  • L. Di Lauro, P. Vici, F. Belli, S. Tomao i inni. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. „Gastric Cancer”. 17 (4), s. 718–724, Oct 2014. DOI: 10.1007/s10120-013-0321-3. PMID: 24318671. 
  • A. Inal, M.A. Kaplan, M. Kucukoner, A. Isikdogan. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. „Neoplasma”. 59 (2), s. 233–236, 2012. PMID: 22248282. 
  • S.E. Al-Batran, J.T. Hartmann, R. Hofheinz, N. Homann i inni. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. „Ann Oncol”. 19 (11), s. 1882–1887, Nov 2008. DOI: 10.1093/annonc/mdn403. PMID: 18669868. 
  • E. Van Cutsem, C. Boni, J. Tabernero, B. Massuti i inni. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. „Ann Oncol”. 26 (1), s. 149–156, 2015. DOI: 10.1093/annonc/mdu496. PMID: 25416687. 
  • E. Van Cutsem, V.M. Moiseyenko, S. Tjulandin, A. Majlis i inni. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. „J Clin Oncol”. 24 (31), s. 4991–4997, Nov 2006. DOI: 10.1200/JCO.2006.06.8429. PMID: 17075117. 
  • Y.K. Kang, W.K. Kang, D.B. Shin, J. Chen i inni. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. „Ann Oncol”. 20 (4), s. 666–673, Apr 2009. DOI: 10.1093/annonc/mdn717. PMID: 19153121. 
  • A.F. Okines, A.R. Norman, P. McCloud, Y.K. Kang i inni. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. „Ann Oncol”. 20 (9), s. 1529–1534, Sep 2009. DOI: 10.1093/annonc/mdp047. PMID: 19474114. 
  • M. Dank, J. Zaluski, C. Barone, V. Valvere i inni. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. „Ann Oncol”. 19 (8), s. 1450–1457, Aug 2008. DOI: 10.1093/annonc/mdn166. PMID: 18558665. 
  • M. Moehler, S. Kanzler, M. Geissler, J. Raedle i inni. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. „Ann Oncol”. 21 (1), s. 71–77, Jan 2010. DOI: 10.1093/annonc/mdp269. PMID: 19605504. 
  • R. Guimbaud, C. Louvet, P. Ries, M. Ychou i inni. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. „J Clin Oncol”. 32 (31), s. 3520–3526, Nov 2014. DOI: 10.1200/JCO.2013.54.1011. PMID: 25287828. 
  • W. Koizumi, H. Narahara, T. Hara, A. Takagane i inni. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. „Lancet Oncol”. 9 (3), s. 215–221, Mar 2008. DOI: 10.1016/S1470-2045(08)70035-4. PMID: 18282805. 
  • J.A. Ajani, W. Rodriguez, G. Bodoky, V. Moiseyenko i inni. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. „J Clin Oncol”. 28 (9), s. 1547–1553, Mar 2010. DOI: 10.1200/JCO.2009.25.4706. PMID: 20159816. 
  • J.A. Ajani, M. Buyse, M. Lichinitser, V. Gorbunova i inni. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. „Eur J Cancer”. 49 (17), s. 3616–3624, Nov 2013. DOI: 10.1016/j.ejca.2013.07.003. PMID: 23899532. 
  • H.S. Kim, H.J. Kim, S.Y. Kim, T.Y. Kim i inni. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. „Ann Oncol”. 24 (11), s. 2850–2854, Nov 2013. DOI: 10.1093/annonc/mdt351. PMID: 23942775. 
  • D.H. Mi, Z. Li, K.H. Yang, N. Cao i inni. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. „Int J Hyperthermia”. 29 (2), s. 156–167, 2013. DOI: 10.3109/02656736.2013.768359. PMID: 23418917. 
  • G. Matharu, O. Tucker, D. Alderson. Systematic review of intraperitoneal chemotherapy for gastric cancer. „Br J Surg”. 98 (9), s. 1225–1235, Sep 2011. DOI: 10.1002/bjs.7586. PMID: 21644239. 
  • F. Coccolini, E. Cotte, O. Glehen, M. Lotti i inni. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. „Eur J Surg Oncol”. 40 (1), s. 12–26, Jan 2014. DOI: 10.1016/j.ejso.2013.10.019. PMID: 24290371. 
  • Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung i inni. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. „Lancet”. 376 (9742), s. 687–697, Aug 2010. DOI: 10.1016/S0140-6736(10)61121-X. PMID: 20728210. 
  • H. Wilke, K. Muro, E. Van Cutsem, S.C. Oh i inni. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. „Lancet Oncol”. 15 (11), s. 1224–1235, Oct 2014. DOI: 10.1016/S1470-2045(14)70420-6. PMID: 25240821. 
  • E. Santoro. The history of gastric cancer: legends and chronicles. „Gastric Cancer”. 8 (2), s. 71–74, 2005. DOI: 10.1007/s10120-005-0325-8. PMID: 15864712. 
  • S.H. Yan. An early history of human breast cancer: West meets East. „Chin J Cancer”. 32 (9), s. 475–477, Sep 2013. DOI: 10.5732/cjc.013.10097. PMID: 23958056. 
  • D.Y. Graham. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. „World J Gastroenterol”. 20 (18), s. 5191–5204, May 2014. DOI: 10.3748/wjg.v20.i18.5191. PMID: 24833849. 
  • M. Schauer, M. Peiper, J. Theisen, W. Knoefel. Prognostic factors in patients with diffuse type gastric cancer (linitis plastica) after operative treatment. „Eur J Med Res”. 16 (1), s. 29–33, Jan 2011. PMID: 21345767. 
  • G. McNeer, D.A. Sunderland, G. McInnes, H.J. Vandenberg i inni. A more thorough operation for gastric cancer; anatomical basis and description of technique. „Cancer”. 4 (5), s. 957–967, Sep 1951. PMID: 14879360. 
  • S. Kitano, Y. Iso, M. Moriyama, K. Sugimachi. Laparoscopy-assisted Billroth I gastrectomy. „Surg Laparosc Endosc”. 4 (2), s. 146–148, Apr 1994. PMID: 8180768. 
  • J.S. MacDonald, P.S. Schein, P.V. Woolley, T. Smythe i inni. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. „Ann Intern Med”. 93 (4), s. 533–536, Oct 1980. PMID: 7436184. 
  • S.A. Cullinan, C.G. Moertel, T.R. Fleming, J.R. Rubin i inni. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. „JAMA”. 253 (14), s. 2061–2067, Apr 1985. PMID: 2579257. 
  • B.I. Hirschowitz, L.E. Curtiss, C.W. Peters, H.M. Pollard. Demonstration of a new gastroscope, the fiberscope. „Gastroenterology”. 35 (1), s. 50; discussion 51–53, Jul 1958. PMID: 13562387. 
  • B. SCHARRER, M.S. LOCHHEAD. Tumors in the invertebrates: a review. „Cancer Res”. 10 (7), s. 403–419, Jul 1950. PMID: 15427079. 
  • D. Martineau, K. Lemberger, A. Dallaire, P. Labelle i inni. Cancer in wildlife, a case study: beluga from the St. Lawrence estuary, Québec, Canada. „Environ Health Perspect”. 110 (3), s. 285–292, Mar 2002. PMID: 11882480. 
  • M. Kurihara. Inducement of canine gastric cancer by N-ethyl-N'-nitro-N-nitrosoguanidine (ENNG). „Gastric Cancer”. 1 (2), s. 95–103, Mar 1998. DOI: 10.1007/s101209800001. PMID: 11957052. 
  • J. Robert. Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates. „Dev Comp Immunol”. 34 (9), s. 915–925, Sep 2010. DOI: 10.1016/j.dci.2010.05.011. PMID: 20553753. 

onkologia.org.pl

scirp.org

file.scirp.org

springer.com

link.springer.com

termedia.pl

  • Małgorzata Malinowska, Anna Nasierowska-Guttmejer. Epidemiologia i patogeneza raka żołądka. „Polish Journal of Pathology”, 2013. [dostęp 2015-04-15]. 
  • Anna Nasierowska-Guttmejer, Przemysław Majewski, Małgorzata Malinowska. Rak żołądka. Morfologia. „Pol J Pathol”, 2013. 
  • Anna Nasierowska-Guttmejer, Przemysław Majewski, Małgorzata Malinowska. Rak żołądka. Morfologia. „Pol J Pathol”, 2013. 

vetpol.org.pl

web.archive.org

who.int

zalecenia.med.pl

onkologia.zalecenia.med.pl